Selected article for: "active site and infection treatment"
Author: Rhein, Bethany A.; Powers, Linda S.; Rogers, Kai; Anantpadma, Manu; Singh, Brajesh K.; Sakurai, Yasuteru; Bair, Thomas; Miller-Hunt, Catherine; Sinn, Patrick; Davey, Robert A.; Monick, Martha M.; Maury, Wendy
Title: Interferon-? Inhibits Ebola Virus Infection
  • Document date: 2015_11_12
    • ID: 10bu7iwg_22
    Snippet: To assess the impact of IFNγ treatment on cells at the site of infection, peritoneal cells were isolated 24 hours following EBOV GP/rVSV infection of untreated or IFNγ-treated mice. IFNγ treated peritoneal cells had reduced viral RNA levels compared to infected, PBS-treated control cells, regardless of whether IFNγ was given 24 hours prior to, 2, 6 or 12 hours following challenge. These findings suggest that active infection at the site of ch.....
    Document: To assess the impact of IFNγ treatment on cells at the site of infection, peritoneal cells were isolated 24 hours following EBOV GP/rVSV infection of untreated or IFNγ-treated mice. IFNγ treated peritoneal cells had reduced viral RNA levels compared to infected, PBS-treated control cells, regardless of whether IFNγ was given 24 hours prior to, 2, 6 or 12 hours following challenge. These findings suggest that active infection at the site of challenge is ongoing at 24 hours following infection and that IFNγ administration either before or at early time points following infection is able to profoundly reduce virus load at the site of virus challenge (Fig 5C) .

    Search related documents:
    Co phrase search for related documents
    • active infection and early time: 1, 2
    • active infection and infection follow: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and infection site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active infection and RNA level: 1, 2
    • active infection and virus challenge: 1, 2
    • active infection and virus load: 1, 2, 3
    • challenge site and infection site: 1, 2
    • challenge site and virus challenge: 1, 2
    • challenge site and virus challenge site: 1, 2
    • control cell and EBOV GP rvsv: 1
    • control cell and EBOV GP rvsv infection: 1
    • control cell and GP rvsv: 1
    • control cell and infection site: 1
    • control cell and RNA level: 1, 2
    • control cell and virus challenge: 1, 2, 3, 4
    • control cell and virus load: 1
    • early time and infection follow: 1
    • early time and infection site: 1, 2, 3
    • early time and RNA level: 1